Thelansis

 Systemic Mastocytosis (SM) is a rare hematological neoplasm characterized by heterogeneous clinical manifestations due to the excessive proliferation of abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous sites, such as bone marrow (BM), spleen, lymph nodes, and the gastrointestinal (GI) tract. Most cases of systemic mastocytosis are caused by somatic mutations in the KIT gene. This gene encodes a protein that helps control many important cellular processes such as cell growth and division; survival; and movement. Mutations in the KIT gene lead to an overproduction of mast cells, which then accumulate in internal organs and lead to the symptoms of this condition. The long-term outlook (prognosis) for people with systemic mastocytosis (SM) varies. Young children and those who present with primarily cutaneous and flushing symptoms tend to have little or no progression of the disease over a considerable length of time. Older patients and those with extensive, s...

 Systemic Mastocytosis (SM) is a rare hematological neoplasm characterized by heterogeneous clinical manifestations due to the excessive proliferation of abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous sites, such as bone marrow (BM), spleen, lymph nodes, and the gastrointestinal (GI) tract. Most cases of systemic mastocytosis are caused by somatic mutations in the KIT gene. This gene encodes a protein that helps control many important cellular processes such as cell growth and division; survival; and movement. Mutations in the KIT gene lead to an overproduction of mast cells, which then accumulate in internal organs and lead to the symptoms of this condition. The long-term outlook (prognosis) for people with systemic mastocytosis (SM) varies. Young children and those who present with primarily cutaneous and flushing symptoms tend to have little or no progression of the disease over a considerable length of time. Older patients and those with extensive, s...

Systemic Mastocytosis (SM) is a rare hematological neoplasm characterized by heterogeneous clinical manifestations due to the excessive proliferation of abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous sites, such as bone marrow (BM), spleen, lymph nodes, and the gastrointestinal (GI) tract. Somatic mutations in the KIT gene cause most cases of systemic mastocytosis. This gene encodes a protein that helps control critical cellular processes such as cell growth and division, survival, and movement. Mutations in the KIT gene lead to an overproduction of mast cells, which accumulate in internal organs and lead to the symptoms of this condition. The long-term outlook (prognosis) for people with systemic mastocytosis (SM) varies. Young children and those who present with primarily cutaneous and flushing symptoms tend to have little or no progression of the disease over a considerable length of time. Older patients and those with extensive, systemic diseases involvi...